- 1. (Currently amended) A method of treating a patient to alleviate pain <u>treatable with an opioid agonist analgesic</u> without addiction, comprising: administering systemically an amount of noribogaine or its pharmaceutically acceptable salt in the absence of an opioid analgesic to said patient effective to reduce or eliminate pain in said patient.
- 2. (Previously presented) The method of claim 1, wherein said patient is administered a pharmaceutical composition comprising said noribogaine or its salt and wherein said noribogaine is the sole analysesic agent in said pharmaceutical composition.

## 3. Cancelled.

- 4. (Previously presented) The method of any of claims 1-2, wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight.
- 5. (Previously presented) The method of claim 4, wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.
- 6. (Currently amended) A method of treating a patient to alleviate pain <u>treatable with an</u> opioid agonist analgesic, comprising:
- a) administering systemically to said patient an amount of noribogaine or its pharmaceutically acceptable salt; and
- b) concomitantly administering systemically to said patient an amount of one or more opioid antagonists; wherein said respective amounts of noribogaine and said one or more opioid antagonists are effective to reduce or eliminate pain in said patient.
- 7. (Original) The method of claim 6, wherein said opioid antagonist is naloxone, administered to said patient at a dose between 0.05 mg and 0.5 mg for each mg of noribogaine.
- 8. (Original) The method of claim 6, wherein said opioid antagonist is naltrexone, administered to said patient at a dose of between 0.05 mg and 0.5 mg for each mg of noribogaine.
  - 9. (Original) The method of claim 6, wherein said noribogaine and said opioid

antagonist are administered transdermally.

Claims 10-24. Cancelled.

- 25. (Previously presented) A method of treating a patient to alleviate pain <u>treatable with an opioid agonist analgesic</u> without addiction, comprising: administering systemically a pharmaceutical composition consisting essentially of an effective amount of noribogaine or its pharmaceutically acceptable salt to said patient effective to reduce or eliminate <u>said</u> pain in said patient.
- 26. (Previously presented) The method of claim 25, wherein said noribogaine or its salt is the sole analgesic agent in said pharmaceutical composition.
- 27. (Previously presented) The method of 25, wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight.
- 28. (Previously presented) The method of 26, wherein said noribogaine or its salt is administered to said patient at a dose of between 0.1 mg and 100 mg per kg of body weight
- 29. (Previously presented) The method of claim 27, wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.
- 30. (Previously amended) The method of claim 28, wherein said noribogaine or its salt is administered at a dose of between 1.0 mg and 30 mg per kg of body weight.

-3-